The meeting will be held on February 7, 2018 at 6:00 p.m. and end February 8, 2018 9:00 p.m. The meeting location remains the same. The meeting is closed to the public.


Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2018–02031 Filed 1–31–18; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Nanotechnology Study Section, February 8, 2018, 8:00 a.m. to February 9, 2018, 5:00 p.m., Baltimore Marriott Waterfront, 700 Aliceanna Street, Baltimore, MD 21202 which was published in the Federal Register on January 5, 2018, V–83 Pg. 683.

The meeting will be held on February 7, 2018 at 7:00 p.m. and end February 9, 2018 at 5:00. The meeting location remains the same. The meeting is closed to the public.


Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2018–02034 Filed 1–31–18; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Advisory Committee for Women’s Services (ACWS); Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given of a meeting of the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Advisory Committee for Women’s Services (ACWS) on February 14, 2018.

The meeting will include discussions on assessing SAMHSA’s current strategies related to women experiencing homelessness with behavioral health needs, and SAMHSA’s strategies related to women in the criminal justice system with behavioral health needs. Additionally, the ACWS will be speaking with the Assistant Secretary of Mental Health and Substance Use regarding priorities and directions around behavioral health services and access for women and children.

The meeting is open to the public and will be held at SAMHSA, 5600 Fishers Lane, Rockville, MD 20857, in Conference Room 5E29. Attendance by the public will be limited to space available. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions should be forwarded to the contact person (below) by February 5, 2018. Oral presentations from the public will be scheduled at the conclusion of the meeting. Individuals interested in making oral presentations are encouraged to notify the contact person on or before February 5, 2018. Five minutes will be allotted for each presentation.

The meeting may be accessed via telephone. To attend on site, obtain the call-in number and access code, submit written or brief oral comments, or request special accommodations for persons with disabilities, please register on-line at http://nac.samhsa.gov/Registration/meetingsRegistration.aspx, or communicate with SAMHSA’s Designated Federal Officer, Ms. Valerie Kolick (see contact information below).

Substantive meeting information and a roster of ACWS members may be obtained either by accessing the SAMHSA Committee’s Web https://www.samhsa.gov/about-us/advisory-councils/meetings, or by contacting Ms. Kolick.

Committee Name: Substance Abuse and Mental Health Services Administration Advisory Committee for Women’s Services (ACWS).

Date/Time/Type: Wednesday, February 14, 2018, from: 9:00 a.m. to 4:45 p.m. EDT, Open.

Place: SAMHSA, 5600 Fishers Lane, Conference Room 5E29, Rockville, Maryland 20857.

Contact: Valerie Kolick, Designated Federal Official, SAMHSA’s Advisory Committee for Women’s Services, 5600 Fishers Lane, Rockville, MD 20857, Telephone: (240) 276–1738, Email: Valerie.kolick@samhsa.hhs.gov.

Carlos Castillo,
Committee Management Officer, Substance Abuse and Mental Health Services Administration.

[FR Doc. 2018–02010 Filed 1–31–18; 8:45 am]
BILLING CODE 4162–20–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (ITTF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines).

A notice listing all currently HHS-certified laboratories and ITTFs is published in the Federal Register during the first week of each month. If any laboratory or ITTF certification is suspended or revoked, the laboratory or ITTF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines.

If any laboratory or ITTF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter.

This notice is also available on the internet at http://www.samhsa.gov/workplace.

FOR FURTHER INFORMATION CONTACT:
Giselle Hersh, Division of Workplace Programs, SAMHSA/CSAP, 5600 Fishers Lane, Room 16N03A, Rockville, Maryland 20857; 240–276–2600 (voice).

SUPPLEMENTARY INFORMATION: The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (ITTF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); April 30, 2010 (75 FR 22809); and on January 23, 2017 (82 FR 770).

The Mandatory Guidelines were initially developed in accordance with...
Executive Order 12564 and section 503 of Public Law 100–71. The “Mandatory Guidelines for Federal Workplace Drug Testing Programs,” as amended in the revisions listed above, requires strict standards that laboratories and IITFs must meet in order to conduct drug and specimen validity tests on urine specimens for federal agencies.

To become certified, an applicant laboratory or IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory or IITF must participate in a quarterly performance testing program plus undergo periodic, on-site inspections.

Laboratories and IITFs in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA), which attests that it has met minimum standards.

In accordance with the Mandatory Guidelines dated January 23, 2017 (82 FR 7920), the following HHS-certified laboratories and IITFs meet the minimum standards that laboratories and IITFs must meet in order to conduct drug and specimen validity tests on urine specimens:

**HHS-Certified Instrumented Initial Testing Facilities**

Dynacare, 6628 50th Street NW, 
Edmonton, AB Canada T6B 2N7, 780–784–1190 (Formerly: Gamma-Dynacare Medical Laboratories).

**HHS-Certified Laboratories**

ACM Medical Laboratory, Inc., 160 

Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504–361–8989/ 
800–433–3823 (Formerly: Kroll Laboratory Specialists, Inc., Laboratory Specialists, Inc.).

Alere Toxicology Services, 450 

Baptist Medical Center-Toxicology 
Laboratory, 11401 I–30, Little Rock, AR 72209–7056, 501–202–2783 
(Formerly: Forensic Toxicology Laboratory Baptist Medical Center). 

Clinical Reference Laboratory, Inc., 8433 
Quivira Road, Lenexa, KS 66215–2802, 800–445–6917. 

DrugScan, Inc., 200 Precision Road, 

Dynacare ‘, 245 Pall Mall Street, 
London, ONT, Canada N6A 1P4, 519–679–1630. (Formerly: Gamma-
Dynacare Medical Laboratories).

ElSohly Laboratories, Inc., 5 Industrial 
Park Drive, Oxford, MS 38655, 662–236–2609. 

Laboratory Corporation of America 
Holdings, 7207 N. Gessner Road, 
Houston, TX 77040, 713–856–8288/800–800–2387. 

Laboratory Corporation of America 

Laboratory Corporation of America 
Holdings, 1904 TW Alexander Drive, 

Laboratory Corporation of America 
Holdings, 1210 Main Street, 
Southaven, MS 38671, 866–827–8042/800–233–6339 (Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/National Laboratory Center).

LabOne, Inc. d/b/a Quest Diagnostics, 
10101 Renner Blvd., Lenexa, KS 66219, 913–888–3927/800–873–8445 (Formerly: Quest Diagnostics Incorporated: LabOne, Inc.; Center for Laboratory Services, a Division of LabOne, Inc.).

MedTox Laboratories, Inc., 402 W. 
County Road D, St. Paul, MN 55112, 

The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. HHS, with the HHS/NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to be qualified, HHS will recommend that DOT certify the laboratory (Federal Register, July 16, 1996) as meeting the minimum standards of the Mandatory Guidelines published in the Federal Register on January 23, 2017 (82 FR 7920). After receiving DOT certification, the laboratory will be included in the monthly list of HHS-certified laboratories and participate in the NLCP certification maintenance program.

Legacy Laboratory Services—MetroLab, 

Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612–725–2088, Testing for Veterans Affairs (VA) Employees Only.

National Toxicology Laboratories, Inc., 

One Source Toxicology Laboratory, Inc., 
1213 Genoa-Red Bluff, Pasadena, TX 77504, 888–747–3774 (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory).

Pacific Toxicology Laboratories, 9348 
DeSoto Ave., Chatsworth, CA 91311, 
800–328–6942 (Formerly: Centinela Hospital Airport Toxicology Laboratory).

Pathology Associates Medical Laboratories, 


Quest Diagnostics Incorporated, 1777 
Montreal Circle, Tucker, GA 30084, 
800–729–6432 (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories).

Quest Diagnostics Incorporated, 400 
Egyot Road, Norristown, PA 19403, 

Quest Diagnostics Incorporated, 8401 
Falkbrook Ave., West Hills, CA 91304, 
818–737–6370, (Formerly: SmithKline Beecham Clinical Laboratories).

Redwood Toxicology Laboratory, 3700 
Westwind Blvd., Santa Rosa, CA 95403, 800–255–2159. 

STERLING Reference Laboratories, 2617 
East L Street, Tacoma, Washington 
98421, 800–442–0438. 

U.S. Army Forensic Toxicology Drug 
Testing, Laboratory, 2490 Wilson St., 
Fort George G. Meade, MD 20755–5235, 301–677–7085, Testing for 
Department of Defense (DoD) Employees Only.

Charles LoDico, 
Chemist.

[FR Doc. 2018–01931 Filed 1–31–18; 8:45 am] 
BILLING CODE 4160–20–P